INTERACTIONS BETWEEN ANTIPSYCHOTIC AND ANTIHYPERTENSIVE DRUGS

被引:34
作者
MARKOWITZ, JS
WELLS, BG
CARSON, WH
机构
[1] SAMFORD UNIV,SCH PHARM,DEPT PHARM PRACTICE,BIRMINGHAM,AL 35229
[2] MED UNIV S CAROLINA,DEPT HOSP PHARM PRACTICE & ADM,CHARLESTON,SC 29425
[3] MED UNIV S CAROLINA,DEPT PSYCHIAT & BEHAV SCI,CHARLESTON,SC 29425
关键词
D O I
10.1177/106002809502900610
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
OBJECTIVE: TO provide a comprehensive review of the pharmacokinetic and pharmacodynamic interactions between antipsychotics and antihypertensives and to provide recommendations for the selection of antihypertensives in patients receiving antipsychotic therapy. DATA SOURCES: A MEDLINE search of the English-language literature was used to identify pertinent human and animal studies, reviews, and case reports. STUDY SELECTION: All available sources were reviewed. DATA EXTRACTION: Background information was obtained from comprehensive reviews. Individual case reports were assimilated, and pertinent data were extracted. DATA SYNTHESIS: Because hypertension is common in patients with psychiatric illness and antihypertensive agents are used for a multiplicity of indications, significant numbers of patients receive concurrent therapy with antihypertensives and antipsychotics. Many antipsychotics may block the antihypertensive efficacy of guanethidine and related drugs. The interaction between clonidine and antipsychotics is defined less clearly. Limited data suggest possible additive hypotensive effects when chlorpromazine and methyldopa are given in combination. Increased plasma concentrations of thioridazine with a resultant increase in adverse effects have been reported when propranolol or pindolol are added to the regimen. A similar increase in chlorpromazine concentrations has been reported when propranolol was added. Although there are no reports documenting an interaction between a calcium-channel antagonist and an antipsychotic, the possible inhibition of oxidative metabolism of antipsychotics, additive calcium-blocking activity, and additive pharmacodynamic effects are theorized. Hypotension and postural syncope were reported in a patient given therapeutic dosages of chlorpromazine and captopril, and in 2 patients when clozapine was added to enalapril therapy. CONCLUSIONS: No antipsychotic-antihypertensive combination is absolutely contraindicated, but no combination should be considered to be completely without risk. Antihypertensives with no centrally acting activity, such as diuretics, may be the least likely to result in adverse reactions. The combination of the beta-antagonists propranolol or pindolol with thioridazine or chlorpromazine should be avoided if possible. Scrupulous patient monitoring for attenuated or enhanced activity of either agent is essential whenever antipsychotics and antihypertensives are given concurrently.
引用
收藏
页码:603 / 609
页数:7
相关论文
共 50 条
[1]   HYPOTENSION AND CARDIOPULMONARY ARREST ASSOCIATED WITH CONCURRENT HALOPERIDOL AND PROPRANOLOL THERAPY [J].
ALEXANDER, HE ;
MCCARTY, K ;
GIFFEN, MB .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1984, 252 (01) :87-88
[2]  
ALLEN RM, 1979, J CLIN PSYCHIAT, V40, P236
[3]   SYNCOPE ASSOCIATED WITH THE COMBINATION OF CLOZAPINE AND ENALAPRIL [J].
ARONOWITZ, JS ;
CHAKOS, MH ;
SAFFERMAN, AZ ;
LIEBERMAN, JA .
JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY, 1994, 14 (06) :429-430
[4]   MEDICAL ILLNESS IN CHRONIC PSYCHIATRIC OUTPATIENTS [J].
BARNES, RF ;
MASON, JC ;
GREER, C ;
RAY, FT .
GENERAL HOSPITAL PSYCHIATRY, 1983, 5 (03) :191-195
[5]  
BRIANT RH, 1973, BRIT MED J, V852, P522
[6]   THE ROLE OF INDIVIDUAL HUMAN CYTOCHROMES-P450 IN DRUG-METABOLISM AND CLINICAL-RESPONSE [J].
CHOLERTON, S ;
DALY, AK ;
IDLE, JR .
TRENDS IN PHARMACOLOGICAL SCIENCES, 1992, 13 (12) :434-439
[7]  
CHOUINARD G, 1973, CURR THER RES CLIN E, V15, P60
[8]  
CHOUINARD G, 1973, CURR THER RES CLIN E, V15, P473
[9]   PSYCHOSOCIAL FACTORS AND BLOOD-PRESSURE IN THE MICHIGAN STATEWIDE BLOOD-PRESSURE SURVEY [J].
COTTINGTON, EM ;
BROCK, BM ;
HOUSE, JS ;
HAWTHORNE, VM .
AMERICAN JOURNAL OF EPIDEMIOLOGY, 1985, 121 (04) :515-529
[10]   XENOBIOTIC AND ENDOBIOTIC INHIBITORS OF CYTOCHROME-P-450DBL FUNCTION, THE TARGET OF THE DEBRISOQUINE SPARTEINE TYPE POLYMORPHISM [J].
FONNEPFISTER, R ;
MEYER, UA .
BIOCHEMICAL PHARMACOLOGY, 1988, 37 (20) :3829-3835